Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "GABA analogue" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A GABA analogue is a compound which is an analogue or derivative of the neurotransmitter gamma-Aminobutyric acid (GABA) (the IUPAC of which is 4-aminobutanoic acid).
Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
InactiveUS20060264509A1Limited efficacyReduce patient complianceBiocideOrganic active ingredientsGabapentinAdrenergic receptor agonists
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat pain. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g., gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
InactiveUS20040014940A1Carbamic acid derivatives preparationPeptide/protein ingredientsCarbamateCombinatorial chemistry
The synthesis of 1-(acyloxy)-alkyl carbamates of GABA analogs from 1-haloalkyl carbamates of GABA analogs are described. Also described are new 1-haloalkyl carbamates of GABA analogs.
Owner:XENOPORT
Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
Owner:EDUSA PHARMA
Prodrugs of gaba analogs, compositions and uses thereof
InactiveUS20040006132A1Big advantageBiocideCarbamic acid derivatives preparationStereochemistryCommon disease
Owner:XENOPORT
Methods for decreasing detrusor muscle overactivity
InactiveUS20050239890A1Limited efficacyReduce patient complianceBiocideOrganic active ingredientsDiseaseGabapentin
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and / or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs, e.g., gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
InactiveUS20060247311A1Need lessLimited efficacyBiocidePeptide/protein ingredientsDiseaseGabapentinoid
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and / or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Prodrugs of GABA analogs, compositions and uses thereof
Owner:XENOPORT
Regulation of plant fertility by modulation of GABA levels in flowers
The invention provides methods for the alteration of fertility in plants through modulation of floral GABA levels. The techniques of the invention may find use in plant breeding techniques. Also provided by the invention are assays for the screening of candidate modulators of GABA metabolism or GABA analogs through the identification of affects on fertility following application of the candidate modulator to a plant. The technique provides an alternative to animal testing and is amenable to large scale application.
Owner:CHICAGO UNIV OF THE +1
Methods for treating functional bowel disorders using alpha2 subunit calcium channel modulators with smooth muscle modulators
InactiveUS20060276542A1Limited efficacyReduce patient complianceBiocidePeptide/protein ingredientsGabapentinoidAdrenergic receptor agonists
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or, more compounds with smooth muscle modulatory effects to treat functional bowel disorders in patients in need of treatment. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs including gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Method of treating noninflammatory cartilage damage
InactiveUS7189747B2Preventing and treating cartilage damageBiocidePeptide/protein ingredientsHydrogenPharmacology
Owner:WARNER-LAMBERT CO
Gaba conjugates and methods of use thereof
ActiveUS20100113497A1Eliminate side effectsGood curative effectBiocideNervous disorderNeurological disorderGABA analogue
In one aspect, the present invention provides a composition of a covalent conjugate of a GABA analog with a drug. In another aspect, the present invention provides methods for treating pain and neurological disorders using the conjugates of GABA analogs.
Owner:XGENE PHARMA LLC
Ornithine Aminotransferase Inhibition with GABA Analogues for Treatment of Hepatocellular Carcinoma
ActiveUS20160128958A1Inhibit tumor growthShrink tumor sizeHalogenated hydrocarbon active ingredientsBiocideHepatocellular carcinomaGABA analogue
Therapeutic methods relating to the use of GABA-AT inhibitor compounds for the treatment of hepatocellular carcinoma.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT +1
Ornithine aminotransferase inhibition with GABA analogues for treatment of hepatocellular carcinoma
ActiveUS9603820B2Reduced activityReduce and modulate glutamate productionHalogenated hydrocarbon active ingredientsDigestive systemHepatocellular carcinomaGABA analogue
Therapeutic methods relating to the use of GABA-AT inhibitor compounds for the treatment of hepatocellular carcinoma.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT +1
Anti-inflammatory method using gamma-aminobutyric acid (GABA) analogs
InactiveUS6887902B2Preventing and treatingEasy to prepareBiocidePeptide/protein ingredientsGabapentinDisease
GABA analogs such as gabapentin and pregabalin are useful to prevent and treat inflammatory diseases.
Owner:WARNER-LAMBERT CO +1
Gaba analogs, compositions and methods for manufacturing thereof
InactiveUS20080125483A1Improve colonImprove rectal absorption efficiencyBiocideNervous disorderCombinatorial chemistryGABA analogue
Owner:TWI BIOTECH
Liquid pharmaceutical compositions
A liquid pharmaceutical composition of a GABA analog comprising at least one polyhydric alcohol containing 2 to 6 carbon atoms having a pH of about 5.5 to about 7.0 and additionally a two-component liquid pharmaceutical composition comprising a first component comprising a powder mixture comprising a GABA analog and a solid polyhydric alcohol, and a second component comprising a liquid base are described, as well as methods to prepare the compositions and a method for treating cerebral diseases, including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation, renal colic, insomnia, gastrointestinal damage, incontinence, pain, including neuropathic pain, muscular pain, skeletal pain, and migraine using a therapeutically effective amount of the pharmaceutical compositions.
Owner:VIATRIS SPECIALTY LLC
GABA (Gamma-Aminobutyric Acid) conjugates and using method thereof
InactiveCN101898977ANervous disorderGroup 5/15 element organic compoundsGamma-Aminobutyric acidSurgery
On the one hand, the invention provides a composite of covalent conjugates of GABA (Gamma-Aminobutyric Acid) analogues and medicaments, and on the other hand, the invention provides a method for treating pain and neurological disorder by adopting the conjugates of the GABA analogues.
Owner:徐锋
Methods for treating vasomotor symptoms using GABA analogs in a gastric retentive dosage form
ActiveUS8329750B2Improve sleep qualityReduces daytime somnolenceBiocidePeptide/protein ingredientsVasomotor symptomGABA analogue
Owner:DEPOMED SYST INC
Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
InactiveCN1649827AReduce usageExploiting Synthetic PossibilitiesOrganic active ingredientsOrganic compound preparationOctanoic AcidsMedicinal chemistry
The invention relates to a process for preparing highly functionalized gamma- butyrolactams and gamma-amino acids by reductive amination of mucohalic acid or its derivatives, and discloses a process for preparing pregabalin or 3-aminomethyl-5-methyl octanoic acid, GABA analogs with desirable medicinal activity. (Formula I).
Owner:WARNER-LAMBERT CO
Regulation of plant fertility by modulation of GABA levels in flowers
Owner:CHICAGO UNIV OF THE +1
Liquid pharmaceutical composition
The present invention describes liquid pharmaceutical compositions of GABA analogs having a pH of from about 5.5 to about 7.0 comprising at least one polyol containing 2 to 6 carbon atoms and also discloses comprising a first ingredient and a second ingredient two-component liquid pharmaceutical compositions, wherein the first component comprises a powder mixture containing GABA analogs and a solid polyol, and the second component comprises a liquid base; the present invention also describes the use of these compositions. Methods of making and using therapeutically effective amounts of the pharmaceutical compositions to treat the following disorders: Brain disorders, including epilepsy, fainting episodes, hypokinesia, and intracranial trauma; neurodegenerative disorders; depression; mania and bipolar disorder Disorders; anxiety; panic; inflammation; renal colic; insomnia; gastrointestinal impairment; incontinence; pain, including neuropathic pain, myalgia, bone pain, and migraine.
Owner:WARNER LAMBERT CO LLC
Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form
InactiveUS20130158121A1Improve sleep qualityReduces daytime somnolenceBiocideOrganic active ingredientsVasomotor symptomGABA analogue
Owner:DEPOMED SYST INC
Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
The present invention provides cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, methods of making cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs. The present invention also provides methods of using cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs.
Owner:XENOPORT
GABA analog prodrug sustained release oral dosage forms
Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
Owner:XENOPORT
GABA analogs, compositions and methods for manufacturing thereof
InactiveUS7879906B2Improve absorption efficiencyBiocideNervous disorderSynthesis methodsMedicinal chemistry
Owner:TWI BIOTECH
Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form
ActiveUS20090209645A1Improve sleep qualityReduces daytime somnolenceBiocidePeptide/protein ingredientsVasomotor symptomGABA analogue
Owner:DEPOMED SYST INC
Novel gastro-retentive dosage forms
A gastro-retentive pharmaceutical dosage form of a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for formulating for once daily or twice daily administration. Further provided is a method of treating a disorder by administering to a patient in need thereof, a gastro-retentive pharmaceutical dosage form of a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. The opioid is either in slow release form or in immediate release form.
Owner:GRUNENTHAL GMBH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com